位置:首页 > 产品库 > TAT-DEF-Elk-1 TFA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TAT-DEF-Elk-1 TFA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
规格:98%
分子量:3675.09
包装与价格:
包装价格(元)
1mg询价
5mg询价
10mg询价

TAT-DEF-Elk-1 TFA (TDE TFA) 是 Elk-1 的一种可穿透细胞的肽抑制剂,通过模仿和特异性干扰 Elk-1 的 DEF 结构域来实现抑制。TAT-DEF-Elk-1 TFA 阻止 Elk-1 磷酸化并防止 Elk-1 核易位,且不会干扰 ERK 或 MSK1 活化。TAT-DEF-Elk-1 TFA 是分析神经元可塑性发展过程中 Elk-1 在此过程中的作用的有用工具。
货号:ajcx29714
CAS:N/A
分子式:C157H260N57F3O42
分子量:3675.09
溶解度:N/A
纯度:98%
存储:Store at -20°C
库存:现货

Background:

TAT-DEF-Elk-1 TFA (TDE TFA) is a cell-penetrating peptide inhibitor of Elk-1, mimics and specifically interferes with the DEF domain of Elk-1. TAT-DEF-Elk-1 TFA blocks Elk-1 phosphorylation and prevents Elk-1 nuclear translocation without interfering with ERK nor MSK1 activation. TAT-DEF-Elk-1 TFA is a useful tool to analyze the role of Elk-1 in this process during the development of neuronal plasticity[1].

Elk-1 phosphorylation on Ser383/389 has a dual function and triggers both Elk-1 nuclear translocation and SRE-dependent gene expression[1].TAT-DEF-Elk-1 TFA (5 μM; 1 hour) specifically inhibits glutamate-induced elk-1 activation and does not interfer with ERK, MSK-1, or CREB phosphorylation[1].TAT-DEF-Elk-1 TFA (5-10 μM; 2 hour) treatment shows a significant inhibition of c-Fos, Zif268 and JunB, but has no effects on c-Jun expression[1]. Western Blot Analysis[2] Cell Line: Neurons

TAT-DEF-Elk-1 TFA (intraperitoneal injection; 1mg/kg; daily; 14 days) reflects antidepressant efficacy in mice, it decreases immobility similar to the reference antidepressants fluoxetine and desipramine (DMI)[1]. Animal Model: C57Bl6 mice (3-6 months old males) are subjected to social defeat stress[2]

[1]. Lavaur J, et al. A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics.J Neurosci. 2007 Dec 26;27(52):14448-58. [2]. Apazoglou K, et al. Antidepressive effects of targeting ELK-1 signal transduction.Nat Med. 2018 May;24(5):591-597.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024